United Kingdom· GB-APID-45358711000001105
Elahere 100mg/20ml concentrate for solution for infusion vials
A mirvetuximab soravtansine product containing mirvetuximab soravtansine, registered in United Kingdom by AbbVie Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Mirvetuximab soravtansine is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX26 (mirvetuximab soravtansine), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Mirvetuximab soravtansine · ATC L01FX26
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Mirvetuximab soravtansine
- Manufacturer
- AbbVie Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX26
- ATC class
- Mirvetuximab soravtansine
- Defined daily dose
- 18 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin08054083029320
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirvetuximab soravtansine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumElahere 5 mg/mlAbbVie Deutschland
- SwitzerlandElahere
- CzechiaELAHEREAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainELAHERE 5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONAbbvie Deutschland Gmbh & Co. Kg
- FinlandELAHEREAbbVie Deutschland GmbH&Co.KG
- FranceELAHERE 5 mg/mL, solution à diluer pour perfusionABBVIE DEUTSCHLAND (ALLEMAGNE)
- IrelandELAHERE 5 mg/mL concentrate for solution for infusionImmunogen Biopharma (Ireland) Limited
- IcelandELAHEREAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elahere
- Liechtenstein · Elahere
- Norway · Elahere
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b00e8b1c-3167-4f09-80dc-3eebb9117c5b GET /v1/drugs/b00e8b1c-3167-4f09-80dc-3eebb9117c5b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45358711000001105",
"desc": "Elahere 100mg/20ml concentrate for solution for infusion vials (AbbVie Ltd)",
"form": "Solution for infusion",
"vpid": "45391711000001105",
"source": "dmd",
"vtm_id": "45371211000001109",
"strength": "5 mg",
"substance": "Mirvetuximab soravtansine",
"ingredient": "Mirvetuximab soravtansine",
"supplier_code": "20741511000001103"
}See everything about mirvetuximab soravtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.